Font Size: a A A
Keyword [Nivolumab]
Result: 1 - 13 | Page: 1 of 1
1. Targeting NSCLC With Adoptive DNT Cell Transfer In Combination With Anti-PD1 Blockade
2. The Role And Mechanisms Of Gut Microbiota In Responses To Immunotherapy
3. Efficacy And Treatment-related Toxicities Associated With PD-1/PD-L1 Inhibitors In Previously-treated Advanced Non-small Cell Lung Cancer(NSCLC):Systematic Review And Meta-analysis
4. The Incidence And Risk Factors Of Pneumonitis In Patients Treated With Immune Checkpoint Inhibitors
5. Clinical Pathological Characteristics Of Liver Injury Associated With Immune Checkpoint Inhibitors
6. Risk Of Immune-Related Adverse Events Associated With Ipilimumab-Plus-Nivolumab And Nivolumab Therapy In Cancer Patients
7. Construction Of Recombinant Adenovirus Expressing Full-length PD-1 Antibody,Nivolumab
8. Incidence And Risk Of PD-1/PD-L1 Inhibitors Related Pneumonitis In Patients With Advanced Cancer
9. Relationship Between18f-fluorodeoxyglucose Uptake And Response To PD-1 Inhibitor Nivalumab In Advanced Hepatocellular Carcinoma
10. The Role Of TIM-3 In Tumor Immunity And The Mechanisms Of Action
11. Efficacy And Immune-Related Adverse Events Induced By PD-1/PD-L1 Inhibitors As First-Line Treatment For Advanced Non-Small Cell Lung Cancer:a Meta-Analysis Of Randomized Controlled Trials
12. Analysis Of Differential Genes That Affect The Efficacy Of Nivolumab And Pembrolizumab In The Treatment Of Non-small Cell Lung Cancer Based On GEO Database
13. Meta-analysis Of The Efficacy And Safety Of PD-1 Inhibitors In The Treatment Of Advanced Tumors
  <<First  <Prev  Next>  Last>>  Jump to